After thousands of papers praising the potential of PSMA-based radiopharmaceuticals for the precision medicine of prostate cancer, including the current emphasis on the elusive nature of 225Ac-compounds (Stein and Kerlin 2019; Wilson 2019), this rings an alarm bell that the ‘unclear medicine’ narrative is not going to disappear completely. This evidence concerns the gene FOLH1 and prostate carcinoma.